BioMarin’s $4.8B Acquisition of Amicus Boosts Rare-Disease Portfolio & U.S. Patent Exclusivity
BioMarin will buy Amicus for $4.8B in cash ($...
The deal brings about $599M in trailing annua...
BioMarin will fund the purchase with ~$3.7B o...
Shares jumped (Amicus ~30%, BioMarin ~18%–20%...
The deal brings about $599M in trailing annua...
BioMarin will fund the purchase with ~$3.7B o...
Shares jumped (Amicus ~30%, BioMarin ~18%–20%...
